NCT06526533RecruitingPhase 3
RECOMMEND Platform Trial
Generating New Evidence to Reduce Major Complications to Improve the Safety and Efficacy of ECMO in Severe Cardiac and Respiratory Failure (RECOMMEND)
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 25 Jul 2024
- Start date
- 23 Mar 2026
- Primary completion date
- Jun 2028
- Lead sponsor
- Australian and New Zealand Intensive Care Research Centre
- NCT number
- NCT06526533
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 600
- From 23 Mar 2026 to the primary completion date, Jun 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- PLATFORM INCLUSION CRITERIA:
- Patients receiving ECMO
- Patients enrolled in the EXCEL Registry - NCT03793257
- PLATFORM EXCLUSION CRITERIA:
- Treating clinician regards death as imminent and inevitable
- Treating clinician determines it is not in the patient's best interests
- RBC TRANSFUSION DOMAIN INCLUSION CRITERIA:
- Aged 18 years or older
- RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:
- Contraindication to RBC transfusion (including known patient preference)
- Limitations of care put in place either through patient wishes or the treating medical teams.
- Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)
- The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
- The treating physician deems the study is not in the patient's best interest
- The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
- Actively listed for a solid organ transplant and has not yet received one
- Suspected or confirmed to be pregnant
- Previous ECMO treatment during the same hospital admission
Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Prince Alfred Hospital Coordinator of this site? Confirm its status | Camperdown | Australia | Not yet recruiting |
| The Alfred Hospital Coordinator of this site? Confirm its status | Melbourne | Australia | Not yet recruiting |
| St Vincent's Hospital Sydney Coordinator of this site? Confirm its status | Sydney | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.